COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 14th April 2020. As a result, our offices will now be closed till 14th April 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details. editor@innovativepublication.com, rakesh.its@gmail.com, Mob. 8826373757, 8826859373, 9910947804

Article view: 480

Article download: 162

IP Indian Journal of Immunology and Respiratory Medicine


Starting a newer shorter MDR regimen for MDR-TB at a district TB center for the first time- A case report from a heavy center in Western Delhi


Full Text PDF Share on Facebook Share on Twitter


Author Details : Mohammad Atif, Sankalp Yadav, Mohd Maroof

Volume : 3, Issue : 2, Year : 2018

Article Page : 87-89


Suggest article by email

Abstract

Drug Resistant TB is a challenge for a country like India where there is highest prevalence of MDR cases in the world. With decentralizing and smooth accessibility of the Gene Xpert, it has become quick and easy to rule out the drug resistance. Unlike the conventional CAT-IV treatment of about 24 months, a newer shorter regimen of MDR TB treatment has been started in selected cases like pulmonary MDR-TB (when there is no resistance of FQs% or SLIs on the second line LPA). We herein, present a case of secondary pulmonary MDR-TB, who has been started on a newer shorter MDR regimen treatment for the first time at a very large and heavily burdened center in the Western part of the national capital of India.

Keywords: Gene Xpert; LPA; MDR; SLI; TB.

Doi : 10.18231/2581-4222.2018.0023

How to cite : Atif M, Yadav S, Maroof M, Starting a newer shorter MDR regimen for MDR-TB at a district TB center for the first time- A case report from a heavy center in Western Delhi. IP Indian J Immunol Respir Med 2018;3(2):87-89

Copyright © 2018 by author(s) and IP Indian J Immunol Respir Med. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (creativecommons.org)